Literature DB >> 10972370

Molecular epidemiology of a large outbreak of hepatitis B linked to autohaemotherapy.

G J Webster1, R Hallett, S A Whalley, M Meltzer, K Balogun, D Brown, C P Farrington, S Sharma, G Hamilton, S C Farrow, M E Ramsay, C G Teo, G M Dusheiko.   

Abstract

BACKGROUND: Unregulated skin-piercing procedures potentially facilitate the transmission of bloodborne pathogens. In February, 1998, a patient who had recently received autohaemotherapy at an alternative medicine clinic in the UK was diagnosed with acute hepatitis B. The autohaemotherapy procedure involved the drawing of 1 mL of the patient's blood, mixing with saline, and reinjection of the autologous blood mixture. We investigated the extent of hepatitis B virus (HBV) infection in patients and staff of the clinic.
METHODS: Patients who had attended the clinic between January, 1997, and February, 1998, were tested for serological markers of HBV, and for HBV DNA by PCR. HBV DNA was sequenced to assess the relatedness of the virus identified in the cases. We analysed the number and dates of visits with regard to HBV status.
FINDINGS: Serum samples were received from 352 patients and four staff members. Serological evidence of exposure to HBV was found in 57 (16%). Of the 33 patients and staff who were positive for hepatitis B surface antigen, 30 (91%) showed complete nucleotide identity in the DNA segments derived from the surface and core genes. Five patients with linked infection had markers of chronic hepatitis B, and one of these was regarded as the likely source of the outbreak. The attack rate was associated with the number of visits (p<0.0001) and the week of visit (p=0.011). Contaminated saline in a repeatedly used bottle was the probable vehicle of transmission.
INTERPRETATION: We have described a large community-based outbreak of hepatitis B due to transmission by a single HBV variant. Our findings emphasise the continuing risk of transmission of bloodborne viruses in all health-care settings where skin-piercing procedures are used.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10972370     DOI: 10.1016/S0140-6736(00)02529-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  7 in total

1.  Outbreak of hepatitis B in a nursing home associated with capillary blood sampling.

Authors:  J M Dreesman; A Baillot; L Hamschmidt; M Monazahian; U C Wend; W H Gerlich
Journal:  Epidemiol Infect       Date:  2006-01-26       Impact factor: 2.451

Review 2.  A Review of Integrative Medicine in Gynaecological Oncology.

Authors:  M Kalder; T Müller; D Fischer; A Müller; W Bader; M W Beckmann; C Brucker; C C Hack; V Hanf; A Hasenburg; A Hein; S Jud; M Kiechle; E Klein; D Paepke; A Rotmann; F Schütz; G Dobos; P Voiß; S Kümmel
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-02       Impact factor: 2.915

3.  The role of cells refractory to productive infection in acute hepatitis B viral dynamics.

Authors:  Stanca M Ciupe; Ruy M Ribeiro; Patrick W Nelson; Geoffrey Dusheiko; Alan S Perelson
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-14       Impact factor: 11.205

4.  Modeling the mechanisms of acute hepatitis B virus infection.

Authors:  Stanca M Ciupe; Ruy M Ribeiro; Patrick W Nelson; Alan S Perelson
Journal:  J Theor Biol       Date:  2007-03-12       Impact factor: 2.691

5.  Kinetics of acute hepatitis B virus infection in humans.

Authors:  S A Whalley; J M Murray; D Brown; G J Webster; V C Emery; G M Dusheiko; A S Perelson
Journal:  J Exp Med       Date:  2001-04-02       Impact factor: 14.307

6.  Adult vaccination coverage levels among users of complementary/alternative medicine - results from the 2002 National Health Interview Survey (NHIS).

Authors:  Shannon Stokley; Karen A Cullen; Allison Kennedy; Barbara H Bardenheier
Journal:  BMC Complement Altern Med       Date:  2008-02-22       Impact factor: 3.659

7.  Antibody responses during hepatitis B viral infection.

Authors:  Stanca M Ciupe; Ruy M Ribeiro; Alan S Perelson
Journal:  PLoS Comput Biol       Date:  2014-07-31       Impact factor: 4.475

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.